[Pharmacological treatment of COPD and future of anti-inflammatory therapy].
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. It is caused by chronic inflammation of the airways and the lung parenchyma. Symptomatic treatment is based on bronchodilatation, which leads to a reduction of hyperinflation and relief of dyspnea. Smoking cessation is the only known causative treatment option. Inhaled corticosteroids (ICS) reduce exacerbations and, potentially, mortality. Future therapies should ameliorate chronic inflammation and thus stop the annual decline of lung function. In face of increasing mortality and morbidity more research is needed.
Watz
Henrik
H
Zentrum für Pneumologie und Thoraxchirurgie, Pneumologisches Forschungsinstitut am Krankenhaus Grosshansdorf, Grosshansdorf.
Bitter-Suermann
Stephanie
S
Kanniess
Frank
F
Magnussen
Helgo
H
D000111:Acetylcysteine / Q000008:administration & dosage / Q000627:therapeutic use; D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002264:Carboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000209:etiology; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use; D005541:Forced Expiratory Volume; D005544:Forecasting; D006801:Humans; D007249:Inflammation; D000069285:Infliximab; D008168:Lung / Q000473:pathology; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010865:Pilot Projects; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D012106:Research; D012129:Respiratory Function Tests; D019821:Simvastatin / Q000008:administration & dosage / Q000627:therapeutic use; D016540:Smoking Cessation; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use; D013806:Theophylline / Q000008:administration & dosage / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D001993:Bronchodilator Agents; D002264:Carboxylic Acids; D003509:Cyclohexanecarboxylic Acids; D005100:Expectorants; D018942:Macrolides; D009570:Nitriles; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; C433247:Cilomilast; D019821:Simvastatin; D000069285:Infliximab; D013806:Theophylline; D013752:Tetracycline; D000111:Acetylcysteine